<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39331693</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2141</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>British journal of haematology</Title><ISOAbbreviation>Br J Haematol</ISOAbbreviation></Journal><ArticleTitle>In the SARS-CoV-2 era, do we need to be afraid of obinutuzumab?</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/bjh.19786</ELocationID><Abstract><AbstractText>In their paper, Pinto et al. report findings from the Italian URBAN study; an ambispective, observational, multicentre study evaluating the safety and efficacy of obinutuzumab-based therapy for advanced stage follicular lymphoma (FL) in routine practice. The URBAN substudy reported here examined severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outcomes in 299 patients with treatment-naïve advanced stage FL, treated with obinutuzumab-based chemoimmunotherapy and maintenance. The study began enrolling in September 2019, continuing enrolment throughout the pandemic, with cut-off for the current analysis of 31 January 2022; thus, it provides unique insights into various pandemic phases, including the impact of administration of SARS-CoV-2 vaccination. Commentary on: Pinto et al. Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19661.</AbstractText><CopyrightInformation>British Journal of Haematology© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choy</LastName><ForeName>Joleen</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0701-606X</Identifier><AffiliationInfo><Affiliation>Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>Katharine L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0003-0549-5877</Identifier><AffiliationInfo><Affiliation>Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Western Australia, Nedlands, Western Australia, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Haematol</MedlineTA><NlmUniqueID>0372544</NlmUniqueID><ISSNLinking>0007-1048</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">advanced stage follicular lymphoma</Keyword><Keyword MajorTopicYN="N">obinutuzumab‐based therapy</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>18</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>13</Hour><Minute>45</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331693</ArticleId><ArticleId IdType="doi">10.1111/bjh.19786</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>WHO. COVID‐19 epidemiological update—22 December 2023. WHO; 2023.</Citation></Reference><Reference><Citation>Gong IY, Prica A, Ante Z, Calzavara A, Krzyzanowska MK, Singh S, et al. Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada. Br J Haematol. 2024;204(3):805–814.</Citation></Reference><Reference><Citation>Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first‐line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–1344.</Citation></Reference><Reference><Citation>Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, et al. A prognostic model for patients with lymphoma and COVID‐19: a multicentre cohort study. Blood Adv. 2022;6(1):327–338.</Citation></Reference><Reference><Citation>Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, et al. COVID‐19 in patients receiving CD20‐depleting immunochemotherapy for B‐cell lymphoma. Hemasphere. 2021;5(7):e603.</Citation></Reference><Reference><Citation>Duléry R, Lamure S, Delord M, di Blasi R, Chauchet A, Hueso T, et al. Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944.</Citation></Reference><Reference><Citation>Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti‐CD20 therapy: a systematic review and meta‐analysis of 905 patients. Blood Adv. 2021;5(12):2624–2643.</Citation></Reference><Reference><Citation>Lim SH, Stuart B, Joseph‐Pietras D, Johnson M, Campbell N, Kelly A, et al. Immune responses against SARS‐CoV‐2 variants after two and three doses of vaccine in B‐cell malignancies: UK PROSECO study. Nat Cancer. 2022;3(5):552–564.</Citation></Reference><Reference><Citation>Casulo C, Dixon JG, le‐Rademacher J, Hoster E, Hochster HS, Hiddemann W, et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684–1693.</Citation></Reference><Reference><Citation>Galusic D, Basic‐Kinda S, Pijuk A, Milunovic V, Dreta B, Franjic N, et al. Efficacy and safety of obinutuzumab‐chemotherapy combinations in front‐line treatment of follicular non‐Hodgkin lymphoma during the COVID‐19 pandemic: a study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. Hema. 2022;6(12):e807.</Citation></Reference><Reference><Citation>Paszkiewicz‐Kozik E, Hus I, Palka M, Debowska M, Konska A, Kotarska M, et al. Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: a real‐world retrospective report of the polish lymphoma research group. Adv Clin Exp Med. 2023;32(1):131–136.</Citation></Reference><Reference><Citation>Shafat T, Grupel D, Porges T, Levi I, Yagel Y, Nesher L. Treatment with obinutuzumab leads to worse outcomes in haematological patients diagnosed with Omicron variant COVID‐19. Br J Haematol. 2022;198(5):826–829.</Citation></Reference><Reference><Citation>Levin MJ, Ustianowski A, de Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (tixagevimab‐cilgavimab) for prevention of Covid‐19. N Engl J Med. 2022;386(23):2188–2200.</Citation></Reference><Reference><Citation>Hammond J, Leister‐Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Oral Nirmatrelvir for high‐risk, nonhospitalized adults with Covid‐19. N Engl J Med. 2022;386(15):1397–1408.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>